Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

NEWS Press Release Media Report

Year:

Select

Press Release

17 May 2019

Phase I Clinical Data of KN046, an Innovative PD-L1/CTLA4 Bispecific Antibody of Alphamab Oncology, is to be Presented at the 2019 ASCO Annual Meeting SUZHOU, China, May 17, 2019 – Alphamab Oncology announced today that the phase I clinical trial of KN046 (PD-L1/CTLA4 bispecific antibody) has achieved expected results. Clinical data will be present...
30 April 2019

Alphamab Oncology Initiated KN046 Phase II Clinical Trial in NSCLC Alphamab Oncology announced that phase II clinical trial for non-small cell lung cancer has been launched for KN046, an innovative bispecific antibody developed by the company.
08 March 2019

Alphamab Oncology Reaches a Cooperation Intention with TOT Biopharm to Develop an Innovative Combination Therapy of KN046 and TAB008 Suzhou, March 8, 2019 - Alphamab Oncology and TOT Biopharm Company Limited (TOT Biopharm), both located in Suzhou Industrial Park, jointly announced that they have reached an intention to cooperate an...
25 Janurary 2019

Alphamab Oncology Collaborates with HEC Research Institute on the Combination Therapy of KN046 and CT053 Alphamab Oncology and HEC Pharmaceutical Group Research Institute (HEC Research Institute) announced that they will jointly develop the combination therapy of KN046, a PD-L1/CTLA-4 bispecific antibody...
04 Janurary 2019

Alphamab Oncology is Invited to Present at the 37th Annual J.P. Morgan Healthcare Conference Alphamab Oncology, a clinical-stage biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of world-class innovative therapeutics for cancer treatment, ...
19 November 2018

Alphamab Oncology Completes Series-A Round Financing - Further Strengthening Its Global Innovative Biologics Platforms Alphamab Oncology announced the successful completion of series A financing round, with more than $100 million raised. A number of well-regarded institutional investors, including Advantech Capital, P...
24 October 2018

KN035, a Global Leading Subcutaneously-administered PD-L1 Antibody, Starts Late-stage Clinical Development；KN035's US Phase I clinical data was presented at the annual ESMO Congress SUZHOU, China, Oct. 23, 2018 /PRNewswire/ -- Alphamab Oncology and 3D Medicines Inc. (3D Med) announced today PD-L1 antibody KN035 has entered late stage clinical development
16 October 2018

Alphamab Oncology's HER2 bispecific antibody KN026 gained US IND approval; phase I clinical trial started in China SUZHOU, China, Oct. 16, 2018 /PRNewswire/ -- Alphamab Oncology announced that it has received US FDA's IND approval for its proprietary HER2 bispecific antibody (product code: KN026), and KN026 ...
10 October 2018

Alphamab Oncology's first-in-class PD-L1 - CTLA-4 bispecific antibody KN046 enters clinical trial Alphamab Oncology announced that its proprietary humanized PD-L1 - CTLA-4 bispecific antibody (product code: KN046) program, the first of its class, has recently started phase I clinical trial in Aust...
13 April 2018

Alphamab’s Novel Her-2 Bispecific Antibody KN026 Gains IND Approval in China; CMC Validation of Its Proprietary Bispecific Platform SUZHOU, China--(BUSINESS WIRE)-Suzhou Alphamab Co., Ltd. announced today that the IND for its leading bispecific program KN026 has been approved by the CFDA, marking a significant milestone for Alpham...